Skip to main content

Loading market data...

BMY

Bristol-Myers Squibb Company

NYSE • United states

$61.42

+$2.59

(+4.40%)

Source: Yahoo Finance · Quote time Oct 20, 2026 18:48 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Bristol-Myers Squibb Company (BMY)

Unavailable

Quotes may be delayed

$125.46B

Market Cap

6,787,546

Volume

13.5

P/E Ratio

4.10%

Div Yield

Bristol-Myers Squibb Company Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

7 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Bristol-Myers Squibb Company.

30 Jul 2026

Bristol-Myers Squibb Company filed Form 10-Q

Bristol-Myers Squibb Company submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

30 Jul 2026

Bristol-Myers Squibb Company reported Operating or financial results

Bristol-Myers Squibb Company filed an 8-K covering operating or financial results, Regulation FD disclosure, supporting financial statements or exhibits.

9 May 2026

Bristol-Myers Squibb Company securities registration filing

Bristol-Myers Squibb Company filed a registration or prospectus document concerning securities.

9 May 2026

Bristol-Myers Squibb Company reported Shareholder voting results

Bristol-Myers Squibb Company filed an 8-K covering shareholder voting results.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$8.72B

Total assets (USD)$87.63B

Total liabilities (USD)$65.32B

Shareholders' equity (USD)$22.32B

Long-term debt (USD)$42.09B

Debt due within a year (USD)$768.00M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$12.97B	Unavailable	$3.32B	$1.62	10-Q · 30 Jul 2026
Q1 2026	$11.49B	Unavailable	$2.68B	$1.31	10-Q · 30 Apr 2026
Q4 2025	$12.50B	Unavailable	$1.09B	Unavailable	10-K · 11 Feb 2026
Q3 2025	$12.22B	Unavailable	$2.20B	$1.08	10-Q · 30 Oct 2025
Q2 2025	$12.27B	Unavailable	$1.31B	$0.64	10-Q · 31 Jul 2025
Q1 2025	$11.20B	Unavailable	$2.46B	$1.20	10-Q · 24 Apr 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $66.60

8.4% upside potential

📈

Strong Buy

Unavailable

👍

Buy

9

⏸️

Hold

11

📉

Sell

1

21 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 18:48 UTC Targets range 41.00–82.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

2

Oct 2026

Gallman Cari

EVP, General Counsel

Option exercise

Unavailable per share

4,559 shares

2

Oct 2026

Gallman Cari

EVP, General Counsel

Tax withholding

$61.15 per share

2,332 shares

9

Sep 2026

Massacesi Cristian

EVP,Chief Med Offr,Head of Dev

Open-market sale

$64.57 per share

6,249 shares

1

Sep 2026

Short Bartie Wendy

EVP, Corporate Affairs

Option exercise

$66.92 per share

1,236 shares

1

Sep 2026

Short Bartie Wendy

EVP, Corporate Affairs

Tax withholding

$66.92 per share

633 shares

Top Shareholders

Vanguard Group Inc

198,727,768 shares

1.4% change

12/31/2025

Blackrock, Inc.

180,384,994 shares

5.069% change

6/30/2026

Vanguard Capital Management Llc

133,337,856 shares

0.769% change

6/30/2026

State Street Corp

102,408,940 shares

3.9% change

6/30/2026

Jpmorgan Chase & Co

71,713,442 shares

-22.451% change

6/30/2026

Charles Schwab Investment Management Inc

67,595,177 shares

10.603% change

6/30/2026

Geode Capital Management, Llc

56,443,077 shares

2.093% change

6/30/2026

Vanguard Portfolio Management Llc

46,873,015 shares

1.391% change

6/30/2026

Norges Bank

36,866,658 shares

2.122% change

6/30/2026

Bank Of America Corp /De/

34,045,352 shares

4.475% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 18:48 UTC· 1 day ago

Research coverage and investment tools

Bristol-Myers Squibb Company (BMY) is a stock listed on the New York Stock Exchange in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$61.42 on 20 Oct 2026. That is 72% of the way from its 52-week low of US$42.52 to its 52-week high of US$68.64. It paid US$2.52 a share in dividends over the last 12 months, a dividend yield of 4.10%. The latest ex-dividend date on file is 2 Oct 2026. Its market capitalisation was US$125.46 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$12.97B	Unavailable	$3.32B	$1.62	—	—	$3.09B	10-Q · 30 Jul 2026 (opens in a new tab)
Q1 2026	$11.49B	Unavailable	$2.68B	$1.31	—	—	$757.00M	10-Q · 30 Apr 2026 (opens in a new tab)
Q4 2025	$12.50B	Unavailable	$1.09B	Unavailable	—	—	$1.60B	10-K · 11 Feb 2026 (opens in a new tab)
Q3 2025	$12.22B	Unavailable	$2.20B	$1.08	—	—	$5.99B	10-Q · 30 Oct 2025 (opens in a new tab)
Q2 2025	$12.27B	Unavailable	$1.31B	$0.64	—	—	$3.56B	10-Q · 31 Jul 2025 (opens in a new tab)
Q1 2025	$11.20B	Unavailable	$2.46B	$1.20	—	—	$1.69B	10-Q · 24 Apr 2025 (opens in a new tab)

Cash and equivalents: $8.72B
Total assets: $87.63B
Total liabilities: $65.32B
Shareholders' equity: $22.32B
Long-term debt: $42.09B
Debt due within a year: $768.00M

SCHEDULE 13G · 7 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Bristol-Myers Squibb Company.
10-Q · 30 Jul 2026

Bristol-Myers Squibb Company filed Form 10-Q (opens in a new tab)

Bristol-Myers Squibb Company submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 30 Jul 2026

Bristol-Myers Squibb Company reported Operating or financial results (opens in a new tab)

Bristol-Myers Squibb Company filed an 8-K covering operating or financial results, Regulation FD disclosure, supporting financial statements or exhibits.
S-8 · 9 May 2026

Bristol-Myers Squibb Company securities registration filing (opens in a new tab)

Bristol-Myers Squibb Company filed a registration or prospectus document concerning securities.
8-K · 9 May 2026

Bristol-Myers Squibb Company reported Shareholder voting results (opens in a new tab)

Bristol-Myers Squibb Company filed an 8-K covering shareholder voting results.

Insider	Date	Transaction	Shares	Average price	Filing
Gallman Cari EVP, General Counsel	2 Oct 2026	Option exercise (M)	+4,559	—	Form 4 (opens in a new tab)
Gallman Cari EVP, General Counsel	2 Oct 2026	Tax withholding (F)	−2,332	$61.15	Form 4 (opens in a new tab)
Massacesi Cristian EVP,Chief Med Offr,Head of Dev	9 Sep 2026	Open-market sale (S)	−6,249	$64.57	Form 4 (opens in a new tab)
Short Bartie Wendy EVP, Corporate Affairs	1 Sep 2026	Option exercise (M)	+1,236	$66.92	Form 4 (opens in a new tab)
Short Bartie Wendy EVP, Corporate Affairs	1 Sep 2026	Tax withholding (F)	−633	$66.92	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	198,727,768	1.4%
Blackrock, Inc.	6/30/2026	180,384,994	5.069%
Vanguard Capital Management Llc	6/30/2026	133,337,856	0.769%
State Street Corp	6/30/2026	102,408,940	3.9%
Jpmorgan Chase & Co	6/30/2026	71,713,442	-22.451%
Charles Schwab Investment Management Inc	6/30/2026	67,595,177	10.603%
Geode Capital Management, Llc	6/30/2026	56,443,077	2.093%
Vanguard Portfolio Management Llc	6/30/2026	46,873,015	1.391%
Norges Bank	6/30/2026	36,866,658	2.122%
Bank Of America Corp /De/	6/30/2026	34,045,352	4.475%

Previous close: 58.83 USD
Day range: 59.84 – 61.71 USD
52-week range: 42.52 – 68.64 USD
Volume: 6,787,546
Market cap: $125.46B
Average volume: 11,539,750
P/E ratio: 13.5
EPS (FY 2025, diluted): 3.46 USD
Dividends (last 12 months): 2.52 USD
Dividend yield: 4.10%
Ex-dividend date: 2 Oct 2026
Shares outstanding: 2.04B
Beta (5Y monthly): 0.19

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 18:48 UTC· 1 day ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:08 UTC· 1 hour ago

Dividends: Yahoo Finance dividend history (opens in a new tab) Observed 22 Oct 2026, 06:08 UTC· 1 hour ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding. What dividend yield leaves out: dividend yield vs total return

This research is not available for BMY yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.